Updated on 13 January 2014
Mr Williams explained that the pharmaceutical industry and the pharmaceuticals market in China are both growing rapidly. China is also a large and growing force in the production of generic drugs. China's regulatory and compendial leadership has expressed its commitment to advancing modern, relevant standards for medicines and foods, and USP has joined in this effort via MOUs with ChP, NIFDC and CFSA. Given USP's role in law in the United States, where the current official versions of United States Pharmacopeia and the National Formulary (USP-NF) are referenced and enforceable by the US FDA, USP has also worked closely with FDA and its staff in China to advance good standards for foods and drugs.
"We live in an ever-shrinking world, which makes the quality of products made and sold in China just as important as the quality of products made and sold in the United States," Mr Williams said. "The global flow of products means that quality issues can have a wide impact and having a facility in China allows USP to work more closely with developments in this important industry."